But the fact that up to 10 percent of adults are deficient in the vital DPD enzyme, called Dihydropyrimidine dehydrogenase, is bolstering Mr.
What does DPD stand for?
DPD stands for Dihydropyrimidine Dehydrogenase
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of DPD
We have 151 other meanings of DPD in our Acronym Attic
- Dewan Pimpinan Daerah (Indonesian: Regional Leaders Council)
- Diccionario Panhispánico de Dudas (Spanish)
- Differential Phase Detection
- Digital Photo Display
- Digital Pre-Distortion
- Digital Product Definition
- Digital Product Description
- Digital Product Development
- Digital Publications Development Program (US Army ASRL)
- Dignitary Protection Division (United States Capitol Police)
- Diploma in Practical Dermatology (UK)
- Direct Parcel Distribution (European logistics service)
- Direction de la Programmation et du Développement (French: Department of Programming and Development; French Ministry of Education, Youth and the Voluntary Sector)
- Director of Planning Development (various organizations)
- Director of Professional Development (various organizations)
- Director Personnel Department (US Navy)
- Distal Protection Device (cardiology)
- Distributed Product Description (Modeling and Simulation; Simulation Based Acquisition)
- Distribution Produits Déco (French: Home Products Distribution)
- District Port Director (US Navy)
Samples in periodicals archive:
5FU is initially catabolized to 5-fluorodihydrouracil by dihydropyrimidine dehydrogenase (DPD) mainly in the liver.
Dihydropyrimidine dehydrogenase (DPD) is an enzyme that degrades 5-FU to an inactive metabolite.
Although the cytotoxic effects of 5FU are probably directly mediated via the anabolic pathways, the catabolic route plays an important role because >80% of the administered 5FU is catabolized by dihydropyrimidine dehydrogenase (DPD).
Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications.
Data have suggested that patients who are deficient in the enzyme dihydropyrimidine dehydrogenase (DPD) may be more vulnerable to adverse events with 5-FU, but severe toxicity is extremely rare (about one case in 2 million) with topical formulations.
But another common cause of overexposure is thought to be poor drug clearance: a genetic variation in certain patients results in deficient levels of an enzyme essential for 5-FU metabolism, dihydropyrimidine dehydrogenase (DPD).
Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency.